Most prostate cancers produce no symptoms at all in their early stages. That’s the difficult truth about this disease: you typically can’t feel it, and there’s no single sign that confirms or rules it out on your own. The only reliable way to know is through screening with a PSA blood test, followed by further evaluation if results are concerning. Understanding what to watch for, who should get screened, and what the diagnostic process looks like can help you take the right next step.
Early Prostate Cancer Usually Has No Symptoms
Most prostate cancers grow slowly and don’t cause noticeable problems for years. The CDC states plainly that most men with prostate cancer have no symptoms at all. This is why the disease is so often caught through routine screening rather than because something felt wrong.
When symptoms do appear, they tend to involve urination. These include difficulty starting to urinate, a weak or interrupted stream, needing to urinate frequently (especially at night), trouble emptying your bladder completely, and pain or burning during urination. Blood in the urine or semen and painful ejaculation are also possible signs. The catch is that every one of these symptoms overlaps with benign conditions like an enlarged prostate or a prostate infection, both of which are far more common than cancer. So having these symptoms doesn’t mean you have cancer, and not having them doesn’t mean you’re in the clear.
Signs That Cancer May Have Spread
If prostate cancer advances beyond the gland, it most commonly spreads to the bones. Pain in the lower back, hips, or pelvis that doesn’t go away is the hallmark symptom of metastatic prostate cancer. Unexplained weight loss, fatigue, and fevers can also develop. Bone pain from prostate cancer tends to be persistent and unrelated to physical activity or injury. If you’re experiencing new, unexplained bone pain alongside any urinary changes, that combination warrants prompt medical attention.
Who Is at Higher Risk
Three factors stand out above all others: age, race, and family history. Prostate cancer is rare before age 50 and becomes increasingly common after 55.
Black men in the United States have roughly 67% higher incidence of prostate cancer compared to white men, with about 192 cases per 100,000 men versus 115 per 100,000. This disparity is significant enough that major medical organizations recommend Black men discuss screening earlier than the general population. Asian American and Pacific Islander men have the lowest rates, at about 63 per 100,000.
Genetics matter too. Men who carry a BRCA2 gene mutation, the same gene linked to breast cancer risk, have roughly 3 to 4 times the risk of prostate cancer compared to the general population. BRCA1 mutations carry a smaller increase, around 1.3 to 1.7 times the baseline risk. If close relatives (a father or brother) have had prostate cancer, your own risk is elevated even without a known gene mutation.
The PSA Blood Test
PSA, or prostate-specific antigen, is a protein produced by the prostate. A simple blood draw measures its level. Higher levels can signal cancer, but they can also result from completely benign causes. Prostate inflammation, even without an active infection, raises PSA by disrupting the cells that produce it and making blood vessels in the prostate more permeable, which lets PSA leak into the bloodstream. An enlarged prostate naturally produces more PSA simply because there’s more tissue. Even a recent rectal exam or urinary procedure can temporarily bump the number up.
PSA levels also rise naturally with age. The commonly referenced upper limits by decade are approximately 2.5 ng/mL for men in their 40s, 3.5 for men in their 50s, 4.5 for men in their 60s, and 6.5 for men in their 70s. A result above these thresholds doesn’t confirm cancer. It means further evaluation is worth considering.
When to Start Screening
The U.S. Preventive Services Task Force recommends that men aged 55 to 69 make an individual decision about PSA screening after discussing the benefits and potential downsides with their doctor. For men 70 and older, the task force recommends against routine screening because the slow-growing nature of most prostate cancers means treatment is unlikely to extend life at that age.
The American Urological Association largely agrees with that 55 to 69 window but adds an important note: Black men and men with a family history of prostate cancer should consider starting the conversation about screening before age 55. Both organizations suggest that screening every two to four years, rather than annually, strikes the best balance between catching meaningful cancers and avoiding unnecessary follow-up procedures.
What Happens After an Abnormal PSA
An elevated PSA doesn’t immediately lead to a biopsy. The first step is often a digital rectal exam, where a doctor physically feels the prostate through the rectal wall. A normal prostate feels smooth and slightly firm. What raises concern is a hard area with a sharp edge, an asymmetric shape, or the loss of the normal groove running down the middle of the gland. Nodules caused by infection tend to be raised and blend gradually into surrounding tissue, while suspicious lesions are typically flat, hard, and distinctly bordered.
If the PSA and physical exam together raise enough concern, the next step is increasingly an MRI of the prostate. The images are scored on a 1 to 5 scale called PI-RADS. Scores of 1 and 2 suggest cancer is unlikely, accounting for about one quarter of all prostate MRIs. A score of 3 is considered uncertain. Scores of 4 and 5 indicate that clinically significant cancer is probable. Most doctors recommend a biopsy for scores of 3 or higher, though using a threshold of 4 would miss roughly 16 to 24% of significant cancers depending on the clinical situation.
How a Prostate Biopsy Works
If a biopsy is needed, a thin needle removes small tissue samples from the prostate, guided by ultrasound or MRI. There are two approaches. The transrectal method goes through the rectal wall and typically requires no anesthesia, making it quicker and less expensive. The transperineal method goes through the skin between the scrotum and rectum. It requires some form of anesthesia but carries a significantly lower risk of infection and is better at reaching cancers in the front of the prostate, which the transrectal approach can miss. Current European guidelines now favor the transperineal route, and many hospitals have shifted to it as the default.
Understanding Your Biopsy Results
If cancer is found, it’s graded using two systems that work together. The Gleason score adds together two numbers representing the most common and second most common cell patterns in your sample. In modern practice, the lowest score assigned is 6, which represents the least aggressive cancer. A score of 3+4=7 means most of the cancer looks relatively normal with some poorly formed areas, while 4+3=7 means the reverse, and that distinction matters for prognosis. Scores of 8 through 10 represent progressively more aggressive disease.
Because the Gleason system can be confusing (a 6 sounds like it’s in the middle of a 2-to-10 scale when it’s actually the lowest grade), a newer Grade Group system simplifies things into five categories. Grade Group 1 corresponds to Gleason 6 and has a 96% chance of remaining progression-free five years after surgery. Grade Group 2 (Gleason 3+4) drops to 88%. Grade Group 3 (Gleason 4+3) falls to 63%. Grade Groups 4 and 5, covering Gleason 8 through 10, carry five-year progression-free rates of 48% and 26% respectively. You’ll likely see both systems reported together on your pathology results.
Grade Group 1 cancers are so slow-growing that many men with this result are offered active surveillance, meaning regular monitoring with PSA tests and occasional biopsies, rather than immediate treatment. This approach avoids the side effects of surgery or radiation for a cancer that may never cause harm.